Search

Your search keyword '"Gioulbasanis, Ioannis"' showing total 15 results
Start Over Author "Gioulbasanis, Ioannis" Search Limiters Full Text
15 results on '"Gioulbasanis, Ioannis"'

1. Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

Author

Makrakis, Dimitrios, primary, Rounis, Konstantinos, additional, Tsigkas, Alexandros-Pantelis, additional, Georgiou, Alexandra, additional, Galanakis, Nikolaos, additional, Tsakonas, George, additional, Ekman, Simon, additional, Papadaki, Chara, additional, Monastirioti, Alexia, additional, Kontogianni, Meropi, additional, Gioulbasanis, Ioannis, additional, Mavroudis, i, additional, and Agelaki, Sofia, additional

Published
2023
Full Text
View/download PDF

2. Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

Author

Makrakis, Dimitrios, primary, Rounis, Konstantinos, additional, Tsigkas, Alexandros-Pantelis, additional, Georgiou, Alexandra, additional, Galanakis, Nikolaos, additional, Tsakonas, George, additional, Ekman, Simon, additional, Papadaki, Chara, additional, Monastirioti, Alexia, additional, Kontogianni, Meropi, additional, Gioulbasanis, Ioannis, additional, Mavroudis, Dimitris, additional, and Agelaki, Sofia, additional

Published
2023
Full Text
View/download PDF

4. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss

Author

Johns, Neil, Stretch, Cynthia, Tan, Benjamin H.L., Solheim, Tora S., Sørhaug, Sveinung, Stephens, Nathan A., Gioulbasanis, Ioannis, Skipworth, Richard J.E., Deans, D.A. Christopher, Vigano, Antonio, Ross, James A., Bathe, Oliver F., Tremblay, Michel L., Kaasa, Stein, Strasser, Florian, Gagnon, Bruno, Baracos, Vickie E., Damaraju, Sambasivarao, and Fearon, Kenneth C.H.

Published
2017
Full Text
View/download PDF

6. Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi‐cohort analysis

Author

Martin, Lisa, primary, Muscaritoli, Maurizio, additional, Bourdel‐Marchasson, Isabelle, additional, Kubrak, Catherine, additional, Laird, Barry, additional, Gagnon, Bruno, additional, Chasen, Martin, additional, Gioulbasanis, Ioannis, additional, Wallengren, Ola, additional, Voss, Anne C., additional, Goldwasser, Francois, additional, Jagoe, R. Thomas, additional, Deans, Chris, additional, Bozzetti, Federico, additional, Strasser, Florian, additional, Thoresen, Lene, additional, Kazemi, Sean, additional, Baracos, Vickie, additional, and Senesse, Pierre, additional

Published
2021
Full Text
View/download PDF

7. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study

Author

Rounis, Konstantinos, primary, Makrakis, Dimitrios, additional, Tsigkas, Alexandros-Pantelis, additional, Georgiou, Alexandra, additional, Galanakis, Nikolaos, additional, Papadaki, Chara, additional, Monastirioti, Alexia, additional, Vamvakas, Lambros, additional, Kalbakis, Konstantinos, additional, Vardakis, Nikolaos, additional, Kontogianni, Meropi, additional, Gioulbasanis, Ioannis, additional, Mavroudis, Dimitrios, additional, and Agelaki, Sofia, additional

Published
2021
Full Text
View/download PDF

9. Body composition in patients with non--small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis

Author

Baracos, Vickie E., Reiman, Tony, Mourtzakis, Marina, Gioulbasanis, Ioannis, and Antoun, Sami

Subjects
Cachexia -- Complications and side effects, Lung cancer, Non-small cell -- Care and treatment, Cancer patients -- Prognosis, Cancer patients -- Food and nutrition, Cancer -- Care and treatment, Cancer -- Patient outcomes, Food/cooking/nutrition, Health
Abstract

Background: The prominent clinical feature of cachexia has traditionally been understood to be weight loss; however, in recognition of the potential for divergent behavior of muscle and adipose tissue, cachexia was recently defined as loss of muscle with or without loss of fat mass. Detailed assessments are required to verify body composition in patients with cancer cachexia. Design: We adopted a population-based approach to study body composition in patients with cancer, with the use of diagnostic computed tomography images acquired for cancer diagnosis and follow-up. A prospective cohort of 441 patients with non-small cell lung cancer, who were referred consecutively to a regional medical oncology service in Alberta, Canada, was evaluated. Results: At referral (median time to death: 265 d), mean body mass index (BMI; in kg/[m.sup.2]) was 24.9, with 47.4% of patients being overweight or obese. Only 7.5% overall were underweight as conventionally understood (BMI < 18.5). Analysis of computed tomography images showed extremely high heterogeneity of muscle mass within all strata of BMI. The overall prevalence of severe muscle depletion (sarcopenia) was 46.8% and was present in patients in all BMI categories. A much higher proportion of men (61%) than women (31%) met the criteria for sarcopenia. Conclusions: Wasting of skeletal muscle is a prominent feature of patients with lung cancer, despite normal or heavy body weights. The significance of muscle wasting in normal-weight, overweight, and obese patients as a nutritional risk factor, as a prognostic factor, and as a predictor of cancer treatment toxicity is discussed in this article. Am J Clin Nutr 2010;91(suppl):1133S-7S. doi: 10.3945/ajcn.2010.28608C.

Published
2010

11. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss

Author

Johns, Neil, Stretch, Cynthia, Tan, Benjamin H.L., Solheim, Tora S., Sørhaug, Sveinung, Stephens, Nathan A., Gioulbasanis, Ioannis, Skipworth, Richard J.E., Deans, D.A. Christopher, Vigano, Antonio, Ross, James A., Bathe, Oliver F., Tremblay, Michel L., Kaasa, Stein, Strasser, Florian, Gagnon, Bruno, Baracos, Vickie E., Damaraju, Sambasivarao, and Fearon, Kenneth C.H.

Subjects
Adult, Male, Cachexia, Genotype, Polymorphism, Single Nucleotide, Young Adult, Neoplasms, Weight Loss, Genetics, Humans, Muscle, Skeletal, Letters to the Editor, Letter to the Editor, Cancer, Aged, Retrospective Studies, Aged, 80 and over, Nucleotides, Original Articles, Middle Aged, Muscular Atrophy, Phenotype, Original Article, Female, Polymorphisms, Tomography, X-Ray Computed, Transcriptome
Abstract

BACKGROUND: Cachexia affects the majority with advanced cancer. Based on current demographic and clinical factors, it is not possible to predict who will develop cachexia or not. Such variation may, in part, be due to genotype. It has recently been proposed to extend the diagnostic criteria for cachexia to include a direct measure of low skeletal muscle index (LSMI) in addition to weight loss (WL). We aimed to explore our panel of candidate single nucleotide polymorphism (SNPs) for association with WL +/- computerized tomography-defined LSMI. We also explored whether the transcription in muscle of identified genes was altered according to such cachexia phenotype METHODS: A retrospective cohort study design was used. Analysis explored associations of candidate SNPs with WL (n = 1276) and WL + LSMI (n = 943). Human muscle transcriptome (n = 134) was analysed using an Agilent platform.RESULTS: Single nucleotide polymorphisms in the following genes showed association with WL alone: GCKR, LEPR, SELP, ACVR2B, TLR4, FOXO3, IGF1, CPN1, APOE, FOXO1, and GHRL. SNPs in LEPR, ACVR2B, TNF, and ACE were associated with concurrent WL + LSMI. There was concordance between muscle-specific expression for ACVR2B, FOXO1 and 3, LEPR, GCKR, and TLR4 genes and LSMI and/or WL (P CONCLUSIONS: The rs1799964 in the TNF gene and rs4291 in the ACE gene are new associations when the definition of cachexia is based on a combination of WL and LSMI. These findings focus attention on pro-inflammatory cytokines and the renin-angiotensin system as biomarkers/mediators of muscle wasting in cachexia.

Published
2016

12. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss

Author

Johns, Neil, primary, Stretch, Cynthia, additional, Tan, Benjamin H.L., additional, Solheim, Tora S., additional, Sørhaug, Sveinung, additional, Stephens, Nathan A., additional, Gioulbasanis, Ioannis, additional, Skipworth, Richard J.E., additional, Deans, D.A. Christopher, additional, Vigano, Antonio, additional, Ross, James A., additional, Bathe, Oliver F., additional, Tremblay, Michel L., additional, Kaasa, Stein, additional, Strasser, Florian, additional, Gagnon, Bruno, additional, Baracos, Vickie E., additional, Damaraju, Sambasivarao, additional, and Fearon, Kenneth C.H., additional

Published
2016
Full Text
View/download PDF

15. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.

Author

Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulias V, and Mavroudis D

Subjects
Adult, Aged, Anthracyclines therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bridged-Ring Compounds therapeutic use, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Female, Gefitinib, Humans, Middle Aged, Neoplasm Metastasis, Quinazolines administration & dosage, Quinazolines adverse effects, Taxoids therapeutic use, Vinblastine administration & dosage, Vinblastine adverse effects, Vinblastine analogs & derivatives, Vinorelbine, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
Abstract

Purpose: To determine the tolerability and efficacy of the combination of gefitinib with gemcitabine plus vinorelbine in metastatic breast cancer (MBC) patients, pretreated with anthracyclines and taxanes., Patients and Methods: Women with measurable MBC pretreated with anthracycline- and taxane-based chemotherapy received oral gefitinib (250 mg/day) continuously combined with intravenous gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1, every 2 weeks. The first 10 enrolled patients were evaluated for the safety and tolerability of the proposed fixed-dose regimen., Results: The study was discontinued prematurely due to low accrual. Twenty-five (71%) of the originally scheduled 35 patients received a total of 154 chemotherapy cycles. All the patients had previously received taxane- and 72% additionally anthracycline-based chemotherapy and 64% of them had progressive disease as best response to first-line treatment. Three episodes of dose-limiting toxicities (one non-febrile neutropenia grade 4 and two non-neutropenic infections grade 3) were observed in the safety analysis of the first 10 patients. In an intent-to-treat analysis, the overall response rate was 12% (95% CI, 0-24.7%), the median time to tumour progression was 3.5 months (range 1.0-11.5) and the median overall survival was 10.4 months (range 1.0-46.0). The main toxicity was hematological, with grade 3 and 4 neutropenia occurring in 6 (24%) and 4 (16%) patients, respectively. Febrile neutropenia occurred in 2 (8.0%) patients., Conclusion: Although well tolerated, the gefitinib plus gemcitabine and vinorelbine regimen achieved a low response rate in this prematurely terminated trial and therefore cannot be recommended for women with pretreated MBC.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results